Nanoplex cluster-mediated synergistic modulation of dendritic cells and T cells amplifies tumor-specific adaptive immunity. (PubMed, Biomaterials)
The formulation comprises a nanoplex (NP) encapsulating CpG ODN 1826 (CpG NP), which stimulates TLR-9 and elevates the levels of CD80/86 costimulatory molecules on antigen-presenting cells, and a NP incorporating CTLA-4 siRNA (siCTLA-4 NP), which suppresses the production of the immunological checkpoint molecule CTLA-4 on T cells...Ex-vivo study of cell composition in spleens and tumors, along with tumor-specific antigen stimulation assays on splenocytes, suggests that NC treatment can switch the immunosuppressive tumor microenvironment into an immunocompetent state. These findings demonstrate that our NC formulation, which integrates CTLA-4 suppression with DC stimulation, potentiates immune responses against tumor tissues, providing novel insights and potential applications in the field of cancer immunotherapy.